HilleVax (NASDAQ:HLVX) Trading Up 10%

HilleVax, Inc. (NASDAQ:HLVXGet Free Report) rose 10% during mid-day trading on Tuesday . The company traded as high as $13.64 and last traded at $13.64. Approximately 12,590 shares traded hands during trading, a decline of 92% from the average daily volume of 148,699 shares. The stock had previously closed at $12.40.

Analysts Set New Price Targets

Several analysts have commented on HLVX shares. JPMorgan Chase & Co. lifted their target price on shares of HilleVax from $21.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of HilleVax in a research report on Friday, May 10th.

Get Our Latest Research Report on HilleVax

HilleVax Stock Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 10.92 and a quick ratio of 10.92. The stock has a fifty day moving average of $13.80 and a two-hundred day moving average of $14.93.

HilleVax (NASDAQ:HLVXGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). As a group, equities research analysts predict that HilleVax, Inc. will post -3.14 EPS for the current year.

Insider Activity

In related news, Director Aditya Kohli sold 6,000 shares of HilleVax stock in a transaction on Friday, April 5th. The shares were sold at an average price of $14.44, for a total transaction of $86,640.00. Following the sale, the director now owns 789,776 shares of the company’s stock, valued at approximately $11,404,365.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other HilleVax news, major shareholder Life Sciences X. L.P. Frazier acquired 8,850 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were bought at an average cost of $14.50 per share, for a total transaction of $128,325.00. Following the acquisition, the insider now directly owns 8,544,187 shares of the company’s stock, valued at $123,890,711.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Aditya Kohli sold 6,000 shares of the stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $14.44, for a total value of $86,640.00. Following the transaction, the director now owns 789,776 shares of the company’s stock, valued at $11,404,365.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,898 shares of company stock worth $985,913,906. 71.10% of the stock is currently owned by company insiders.

Institutional Trading of HilleVax

Institutional investors have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C increased its position in shares of HilleVax by 20.3% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company’s stock worth $53,857,000 after purchasing an additional 675,000 shares during the last quarter. Monashee Investment Management LLC bought a new position in HilleVax during the 3rd quarter worth approximately $1,480,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of HilleVax in the 3rd quarter worth approximately $2,374,000. Maven Securities LTD bought a new stake in shares of HilleVax in the 3rd quarter valued at approximately $478,000. Finally, Swiss National Bank raised its position in shares of HilleVax by 47.2% during the 3rd quarter. Swiss National Bank now owns 31,200 shares of the company’s stock valued at $420,000 after acquiring an additional 10,000 shares in the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Further Reading

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.